Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

A Synthetic Cell-Penetrating Peptide Antagonizing TrkA Function Suppresses Neuropathic Pain in Mice

(2010) Wei-Ying Ma et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

(2010) Clara Albanese et al.   MOLECULAR CANCER THERAPEUTICS

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

(2009) D. S. Boss et al.   ANNALS OF ONCOLOGY

Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

(2009) Kamila B. Kurakhmaeva et al.   JOURNAL OF DRUG TARGETING

Identification ofN,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor

(2009) Maria Gabriella Brasca et al.   JOURNAL OF MEDICINAL CHEMISTRY

TrkA overexpression enhances growth and metastasis of breast cancer cells

(2009) C Lagadec et al.   ONCOGENE

The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain

(2008) F De Conno et al.   PALLIATIVE MEDICINE